Study offers clues to brain's protective mechanisms against alcoholism

September 04, 2006

UPTON, NY - Why do some people with a strong family history of alcoholism develop alcohol dependency while others do not? A new study provides clues that differing brain chemistry may provide part of the answer. Researchers from four scientific institutions and federal agencies working at the U.S. Department of Energy's Brookhaven National Laboratory have found that elevated levels of D2 receptors for dopamine -- a chemical "messenger" in the brain's reward circuits -- may provide a protective effect for those most at risk for developing alcoholism. The study, part of an ongoing effort to understand the biochemical basis of alcohol abuse, also provides new evidence for a linkage between emotional attributes and brain function. The study appears in the September 2006 issue of the Archives of General Psychiatry.

"Higher levels of dopamine D2 receptors may provide protection against alcoholism by triggering the brain circuits involved in inhibiting behavioral responses to the presence of alcohol," said lead author Nora D. Volkow, Director of the National Institute on Drug Abuse (NIDA) and former Associate Laboratory Director for life sciences research at Brookhaven Lab. "This means that treatment strategies for alcoholism that increase dopamine D2 receptors could be beneficial for at-risk individuals."

Earlier Brookhaven Lab studies have demonstrated that increasing dopamine D2 receptors by genetic manipulation decreased alcohol consumption in rats that had been trained ( or that were genetically predisposed ( to drink large quantities of alcohol. Another study found that such D2-receptor "gene therapy" reduced drinking in mice with normal to moderately low levels of D2 receptors ( The current study adds to the evidence that D2 receptors modulate the motivation to drink alcohol and that increasing these receptors could play a role in the treatment of alcoholism. The D2 receptor is one of five dopamine receptor subtypes.

In this study, researchers compared the number of dopamine D2 receptors in two groups: 16 nonalcoholic individuals with no family history of alcoholism and 15 nonalcoholic individuals who had a positive family history of alcoholism -- an alcoholic biological father with early onset of alcoholism and at least two other first or second degree relatives (parent, child, sibling, grandparent, grandchild, cousin, aunt, uncle) with alcoholism. The latter group was at a very high risk of developing alcoholism. The researchers studied high-risk individuals rather than looking at people with drinking disorders because chronic alcohol abuse reduces the number of dopamine receptors, making comparisons difficult. Participants were scanned with positron emission tomography (PET) and were given two radioactive tracers to assess their dopamine D2 receptor levels and brain glucose -- a marker of brain function.

The scans demonstrated high levels of dopamine D2 receptors in the brains of participants with a family history of alcoholism, particularly in their frontal regions -- 10 percent higher, on average, than in the brains of those with no family history. These areas of the brain -- including the caudate and ventral striatum -- are involved in emotional reactions to stress and cognitive control of decisions about drinking.

"This suggests that dopamine D2 receptors in these brain regions protect high-risk individuals from becoming alcoholic," said principal investigator Gene-Jack Wang, who chairs Brookhaven Lab's Medical Department and is clinical head of the PET Imaging Group at the Lab's Center for Translational Neuroimaging. "This protective effect may combine with emotional and environmental factors to compensate for higher inherited vulnerability."

Each study participant was given a Multidimensional Personality Questionnaire, to measure for extroversion and introversion, also known as positive and negative emotionality. Positive emotionality is believed to decrease the likelihood of alcohol abuse. This test was given to determine whether the receptors' protective effect was associated with this or other personality characteristics.

"We found that individuals who had the highest level of dopamine D2 receptors were those who were extroverted and more motivated by positive rewards," said Volkow. "This held true for both individuals with and without a family history of alcoholism."
This study was funded by the Office of Biological and Environmental Research within the U.S. Department of Energy's Office of Science and by the Intramural Research Program of the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Study coauthors include Henri Begleiter and Bernice Porjesz, SUNY Downstate Medical Center; and Joanna Fowler, Christopher Wong, Jean Logan, Rita Goldstein, David Axeloff, Peter Thanos, Yeming Ma, and Frank Telang at Brookhaven Lab (with Thanos, Ma and Telang working under the auspices of NIAAA's Intramural Research Program).

DOE has a long-standing interest in research on addiction that builds, as this study does, on the knowledge of brain receptors gained through brain-imaging studies. Brain-imaging techniques such as MRI and PET are a direct outgrowth of DOE's support of basic physics and chemistry research.

Note to local editors: Gene-Jack Wang lives in Port Jefferson, New York.

One of ten national laboratories overseen and primarily funded by the Office of Science of the U.S. Department of Energy (DOE), Brookhaven National Laboratory conducts research in the physical, biomedical, and environmental sciences, as well as in energy technologies and national security. Brookhaven Lab also builds and operates major scientific facilities available to university, industry and government researchers. Brookhaven is operated and managed for DOE's Office of Science by Brookhaven Science Associates, a limited-liability company founded by the Research Foundation of State University of New York on behalf of Stony Brook University, the largest academic user of Laboratory facilities, and Battelle, a nonprofit, applied science and technology organization.

Visit Brookhaven Lab's electronic newsroom for links, news archives, graphics, and more:

DOE/Brookhaven National Laboratory

Related Gene Therapy Articles from Brightsurf:

Risk of AAV mobilization in gene therapy
New data highlight safety concerns for the replication of recombinant adeno-associated viral (rAAV) vectors commonly used in gene therapy.

Discovery challenges the foundations of gene therapy
An article published today in Science Translational Medicine by scientists from Children's Medical Research Institute has challenged one of the foundations of the gene therapy field and will help to improve strategies for treating serious genetic disorders of the liver.

Gene therapy: Novel targets come into view
Retinitis pigmentosa is the most prevalent form of congenital blindness.

Gene therapy targets inner retina to combat blindness
Batten disease is a group of fatal, inherited lysosomal storage disorders that predominantly affect children.

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Restoring vision by gene therapy
Latest scientific findings give hope for people with incurable retinal degeneration.

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

New technology allows control of gene therapy doses
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.

Gene therapy: Development of new DNA transporters
Scientists at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed new delivery vehicles for future gene therapies.

Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.

Read More: Gene Therapy News and Gene Therapy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to